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Abstract
The scope of this chapter is to review the significant effect that nanomedicine 
has had in the treatment of inflammatory diseases. Nanotechnology has been widely 
studied in the last decade and proved to be an encouraging strategy in the health-
care system and the medical field. This novel technology provides a vast number 
of nanomaterials and tools that could actually diagnose and treat different inflam-
matory disorders and conditions. An enormous amount of in vivo and in vitro 
research was conducted by many groups to validate the positive contribution that 
nanoparticles have in regard to the treatment of inflammation and its associated 
illnesses. This contribution is due to the fact that nanoparticles could be modulated 
to pass through metabolic barriers and specifically targeted to deliver drugs to the 
required sites without affecting healthy cells and tissues. This makes them a promis-
ing therapeutical choice for the treatment of inflammatory diseases in the future.
Keywords: nanoparticles, inflammation, nanomedicine, drug delivery, 
nanotechnology
1. Introduction
Along with the advances in drug development recently, a new technology has 
gained a lot of attention in the last decades; this technology is nanotechnology 
[1]. Pharmaceutical industries have become increasingly interested in nanomedi-
cine, due to the huge advantages this technology provides. Nanomedicine is the 
application of nanotechnology to diagnose and treat biological systems in health 
and disease [2]. Nanomedicine has led to the development of powerful tools for 
biological and medical research; these developments include targeted drug deliv-
ery, implantable materials for tissue engineering, and creating nanoscale probes 
for medical diagnostics and tracking cell movements [3]. At times of infection or 
injury, inflammation plays a very important role in protecting the injured tissue 
from further infection by starting the healing process [4]. It does this by increas-
ing blood flow to the damaged tissue, which increases the activity of the cells 
and makes the tissue appear red, hot, and swelling. So, inflammation is actually 
the body’s own response to any damage occurred in the body, which makes it an 
important part of the healing process. However, if inflammation occurs by mistake, 
for example, in autoimmune diseases where the body attacks itself or if the inflam-
mation stays too long, even after the infection or injury had passed, then this could 
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cause an inflammatory disease. Therefore, short periods of inflammation, such 
as with an allergic reaction or with an infection, are generally fully treatable and 
leave no long-term problems. On the other hand, if inflammation lasts more than 
several months or years, then it is particularly severe and may cause lasting damage 
to the affected area or organ, for example, deformed joints. Although, there are an 
extensive number of medications that are available for the treatment of acute and 
chronic inflammation in the market. However, scientists have recently started to 
guide their research toward nanomedicine treatments for inflammatory diseases. 
Many researches have been studied in vivo and in vitro regarding the treatment of 
inflammatory diseases with different kinds of nanoparticles. The results of most of 
the studies reveal a lot of promising and very successful developments. The focus 
of this chapter is to provide an overview in nanotechnology contribution in treating 
inflammatory diseases.
2. Inflammation
When a body is injured or attacked by microbial organisms such as bacteria, 
viruses, or fungi, the immune system is signaled for invaders by the process of 
inflammation. Inflammation is simply the body’s mechanism of defending itself 
by responding to stimuli to repair and heal any signs of damaged cells or tissues. 
That’s why inflammation is an important part of the immune system’s physiologi-
cal response, without which, infections and injuries could become fatal. However, 
if the inflammatory process is not working as it should be, it can turn into a 
disease. Inflammatory diseases include a massive number of disorders and condi-
tions [4–6]. Examples include allergy, asthma, glomerulonephritis, hepatitis, and 
inflammatory bowel disease [5]. Chronic inflammation has been linked to certain 
diseases such as heart disease or stroke and may also lead to autoimmune disor-
ders, such as rheumatoid arthritis or cancer [4].
2.1 Causes of inflammation
An infection or injury affecting the body will most probably trigger a number of 
physical reactions by the immune system that will eventually cause inflammation 
[5]. On the other hand, inflammation in any part of the body does not necessarily 
mean that there is a microbial infection.
The most common causes of inflammation are:
• Pathogens like viruses, bacteria, or fungi
• Injuries like external cuts or wounds
• Chemicals or radiation affecting the lungs or body
Diseases or conditions that can cause inflammation:
• Cystitis: an inflammation of the bladder
• Bronchitis: an inflammation of the bronchi in the lungs
• Otitis media: an inflammation in the middle ear
• Dermatitis: an inflammation of the skin
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2.2 Kinds of inflammation
2.2.1 Acute inflammation
Acute inflammation is a short-term response with localized effects that means it 
works at a specific place where the problem exists. It usually occurs after an injury 
or wound on the skin, a sprained ankle, or a sore throat due to a bacterial infection. 
It starts rapidly, and symptoms are usually severe, but they subside in a couple of 
days or weeks. During an acute inflammation episode, the blood vessels in the area 
affected dilate, and therefore blood flow increases, and the white blood cells cover 
the injured area to promote healing. This response is what causes the injured area to 
turn red and become swollen [5].
2.2.2 Chronic inflammation
Chronic inflammation is a long-term response; it’s mostly a persistent, low-level 
inflammation that can last for months or even a lifetime [7]. Inflammation begins 
as a defensive process in which the body is ready to protect itself from harmful 
pathogens or chemicals that were exposed to the body for a long period of time. 
However, sometimes, this defense mechanism can become uncontrolled, and hence, 
damage to vital organs, nervous and musculoskeletal systems, and blood vessels 
could occur. In some diseases the immune system might attack its own normal cells 
mistaking it for a foreign organism or pathogen, such as in autoimmune disorders, 
causing harmful inflammatory responses.
Chronic inflammatory diseases include:
• Rheumatoid arthritis, where many joints throughout the entire body are perma-
nently inflamed
• Psoriasis, a chronic skin disease
• Inflammations of the bowel such as ulcerative colitis
• Active hepatitis
2.3 Signs and symptoms of inflammation
Signs and symptoms of inflammation can be uncomfortable, but they show 
that the body is trying to heal itself. They vary in severity and intensity depending 
whether the inflammation is acute or chronic. The most important signs that may 
indicate an acute inflammation are [5, 6]:
• Redness: this occurs because the capillaries in the area are filled with more 
blood than usual.
• Heat: this occurs because more blood flows to the affected area, and this makes 
it feel warm to the touch.
• Swelling: this is caused by a buildup of fluid.
• Pain: this is due to the release of chemicals during inflammation that stimulate 
nerve endings, making the area more sensitive to the touch.
• Immobility: there may be some loss of function in the region of the inflammation.
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Not all of the signs must occur simultaneously; some might appear before the 
others. Some inflammations, however, could occur silently without any symptoms, 
especially when the inflammation is deep inside the body such as in an internal 
organ. The loss of function symptom, for example, is when you cannot breathe 
properly if you have asthma, when an inflamed arm or leg is difficult to move 
or when the sense of smell is lost during a nasal allergy. Inflammation does not 
necessarily start exactly when a person has been infected by a virus or bacteria, but 
it actually begins when the body starts to fight against the harmful stimulus or the 
infection.
Symptoms of chronic inflammation present in a different way [5, 7]. These can 
include:
• Constant fatigue
• Mouth sores
• Joint, chest, or abdominal pain
• Rash
• Fever
When people have inflammation, they will feel pain, discomfort, distress, and 
stiffness in the inflamed area, depending on the severity of the inflammation; the 
type of pain varies. Although inflammation, in most cases, does indicate that the 
immune system is working properly, the symptoms are still an unpleasant feeling 
and usually need treatment to ease the pain.
2.4 Treatments of inflammation
The treatment of inflammatory disorders must rely on targets present in the 
diseased tissues [8]. To achieve the desired therapeutic effect on inflammatory 
cells, high drug doses will be required which sometime can induce unwanted 
effects on healthy tissues. The main anti-inflammatory drugs are either steroidal 
such as betamethasone, prednisone, and dexamethasone or nonsteroidal anti-
inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, and naproxen [4]. 
NSAIDs are available in low doses over the counter mostly to treat the pain associ-
ated with inflammation, while higher doses of NSAIDs and steroidal medication 
are available as prescription medications [5]. Both are used to treat acute and 
chronic inflammatory diseases. However, their prolonged use is associated with 
a lot of side effects. Steroidal drugs can cause adrenal atrophy, fluid retention, 
thinning of bones which can lead to osteoporosis, and increased risk of infection 
or injury. NSAIDS can cause peptic ulcers, allergies, high blood pressure, or liver 
and kidney problems. Thus, the search for new anti-inflammatory agents is getting 
popular with the objective to obtain greater safety, better efficacy, and a more 
economical way to treat inflammation [5].
Nanomedicine has grown rapidly due to the need for improved therapies for 
inflammatory, developmental, infectious, and degenerative nervous system dis-
orders [9]. These disorders are a significant burden due to the increased number 
of people affected, disease severity, and financial cost. Therefore, the need for 
an improved diagnosis and treatment is urgent. Nanotechnology has been widely 
studied in the last decade and proved to be an encouraging strategy in the health-
care system and the medical field. This novel technology provides a vast number 
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of nanomaterials and tools that could actually diagnose and treat different inflam-
matory disorders and conditions. This chapter focuses on the current and future 
potential of nanomedicine to positively treat inflammatory disorders.
3. Nanotechnology
The last decade has been a tremendous growth for nanotechnology; it encom-
passes different scientific disciplines. This field aims at designing materials with new 
functions and beneficial properties at the nanometer level [10]. The nanomaterials 
designed are mostly any shape with a size in the range of 1–100 nm [11]. The huge and 
unique advantages that nanoparticles (NPs) offer made them an important research 
in the medical field, which created a new field called nanomedicine [12]. They can 
be used for the prevention, diagnosis, and treatment of many diseases, due to their 
very small size and large surface area. In addition to their easy preparation, NPs can 
be used to encapsulate and protect drugs, genes, or proteins in which they are carry-
ing from degradation, thus, enhancing their biodistribution and allowing sustained 
release [13]. They also improve the bioavailability of hydrophobic molecules and can 
be modulated for site-specific targeting, hence, decreasing the side effects of drugs. 
Moreover, their unique ability to pass through the physiological barriers and intercel-
lular spaces through different mechanisms due to their small size is an important 
property in the treatment of different kinds of diseases such as brain disorders [13]. In 
many cases nowadays, current treatments are simply inadequate to decrease disease 
progression or even remove symptoms and signs of inflammation [9]. However, 
nanoparticles can solve such problems, for example, increasing drug penetration into 
sites of active microbial infection while decreasing its side effects by working as drug 
carriers. In recent years, the goal for nanoparticle development was for the treatment, 
detection, and prevention of inflammatory and infected sites [14–16].
Different types of nanocarriers are available, and they are fabricated and chosen 
depending on different aspects such as the kind of application, what is carried by 
the nanoparticles whether it’s a drug or gene, way of administration, materials 
used, and method of fabrication. Types of nanoparticles include, but not limited 
to, polymeric nanoparticles, solid lipid nanoparticles (SLNs), liposomes, metallic 
nanoparticles, and dendrimers [1]. Below are the different types of nanoparticles 
that are mostly used.
3.1 Polymeric nanoparticles
Polymeric nanoparticles are made from natural or artificial biodegradable and 
biocompatible polymers; they represent a promising formulation for drug delivery 
[17]. They work as carriers to control drug release and target specific locations. 
When compared to conventional formulations, polymeric nanoparticles can 
increase the solubility of the drug, hence, increasing its absorption and reducing the 
therapeutic dose. Furthermore, these nanoparticles are stable and safe. Polymeric 
nanoparticles can be fabricated using various methods of synthesis, according to 
their intended application. They can be designed as nanocapsules or nanospheres 
and range from 10 to 1000 nm in diameter, differing in their composition and 
structural organization [1]. A nanocapsule has a polymeric membrane surround-
ing an oily core in which the active ingredient can be adsorbed to the membrane 
and/or dissolved in the oily core. Nanospheres, on the other hand, are made only 
from a polymeric structure, where the active constituent is adsorbed or retained. 
Polymeric materials that have been used extensively for nanoparticles include poly-
lactic-acid (PLA) and poly-lactic-co-glycolic acid (PLGA) [1, 18].
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3.2 Solid lipid nanoparticles
Solid lipid nanoparticles (SLNs) are colloidal carrier systems that contain highly 
purified triglycerides, composed mainly of lipids. These structures are produced 
from solid lipids and are stabilized by surfactants. They combine the advantages 
of other colloidal systems such as liposomes and polymeric nanoparticles, in their 
biodegradability, biocompatibility, and low toxicity [19]. SLNs can be produced on 
a large scale; they have high physicochemical stability and offer good protection 
against drug degradation [1, 19]. Their size ranges from 50 to 1000 nm and may be 
used in the pharmaceutical field for the delivery of drugs using different routes of 
administration such as oral and parenteral routes [1].
3.3 Liposomes
Liposomes for drug delivery are spherical small-sized vesicles composed of natural 
or synthetic lipid bilayers, separated by an aqueous medium in their core [1, 2, 17]. 
Hydrophilic substances are encapsulated inside the aqueous compartment, while 
lipophilic substances are adsorbed or incorporated in the lipid bilayers. Liposomes are 
classified according to their surface charge, size, lipid composition, and method of 
preparation. The surface charge could be anionic, cationic, or neutral. According to 
the size and number of lamellae, liposomes can be classified as small, large, or giant 
and oligo-, uni- or multi-lamellar, respectively [1]. Liposomes have helped decrease the 
side effects of different drugs such as anticancer and antifungal drugs, simultaneously 
with improving their efficacy [2]. Liposomal drug delivery preparations have also been 
studied in various chronic inflammatory diseases. This is a promising approach since it 
limits the side effects of anti-inflammatory drugs on healthy tissues [2].
3.4 Metallic nanoparticles
Metallic nanoparticles comprise a class of materials that are made from metals 
such as titanium, gold, and platinum. They exhibit remarkable optical and elec-
tronic properties, which make them very useful in the medical field [20]. These 
nanoparticles are ranged in size from 1 to 100 nm, and they can be fabricated and 
modulated with several functional groups, due to their high surface area to volume 
ratio that allows them to be conjugated with antibodies, ligands, and vehicles for 
gene drug delivery and diagnostic imaging [17, 19, 21]. Moreover, metallic nanopar-
ticles have the potential to carry large doses of drugs and increase their circulatory 
half-life [19]. Examples of metallic nanoparticles used in research nowadays include 
but are not limited to gold, silver, zinc oxide, and iron nanoparticles.
3.5 Dendrimers
Dendrimers, one of the most interesting classes of nanoparticles, are synthetic 
polymers with repetitively branched molecules ranging in size from 1 to 100 nm 
[22]. Dendrimers are radially symmetrical molecules with well-defined and 
homogeneous structure consisting of treelike branches [23]. A typical dendrimer 
is composed of different parts; it is composed of a central core surrounded by 
repeated units that start from the inside and grow outward like branches with 
multiple peripheral functional groups [24]. The functional groups have a high 
degree of molecular uniformity and could be adjusted in size, valency, solubility, 
and biodegradation [17]. The dendrimers have very high stability and huge surface 
area, which made them gain a lot of interest and have a wide number of applications 
in the biomedical field.
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4. Contribution of nanoparticles in inflammatory diseases
Pharmacists, physicians, and patients have long desired better pharmaceutical 
formulations to improve drug efficacy, reduce toxicity, and reduce the costs of 
preparation and treatment [2]. The conventional treatments available for inflamma-
tory diseases involve nontargeted treatment options with extensive adverse effects. 
However, nanodrug delivery has shown, in many studies over the years, a numerous 
number of promising approaches for delivery of therapeutic agents, and most of 
them proved to reduce side effects and toxicity, increase a drug’s bioavailability and 
effectiveness at the site, and reduce cost. The focus of this section is to highlight 
the contribution of several nanoparticle applications that have made an immediate 
major impact in the treatment of different inflammatory disorders.
4.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is the most common inflammatory disease and is 
the major cause of disability of the joints [13, 17, 25]. This disease is associated with 
progressive disability, systemic complications, and socioeconomic costs [13, 17]. 
To deliver drugs to the target site directly is still a major problem nowadays. Thus, 
bounding drugs to carriers, like nanoparticles, can make cell-specific targeting 
become more achievable. The drugs available conventionally for the treatment of 
RA include three main groups; these are disease-modifying antirheumatic drugs 
(DMARDs), steroids, and anti-inflammatory drugs such as NSAIDS. Discussed 
below are examples for the contribution of nanoparticles to each group.
In one study scientists explored the use of multifunctional nanoparticles in the 
treatment of RA that involves small synovial joints. This study used near-infrared 
(NIR) light technology along with the nanoparticles [25]. In this study methotrex-
ate (MTX), which is a DMARD, was loaded to a PLGA polymer-gold (Au) half shell 
nanoparticle. Then arginine-glycine-aspartic acid (RGD) peptide was conjugated to 
the surface of the Au NP forming a multifunctional NP (RGD-MTX-PLGA-Au). The 
RGD peptide was used as a targeting moiety for inflammation, the Au half shell was 
used to generate heat, and MTX was used for the treatment of RA. The NPs were 
injected into collagen-induced arthritic (CIA) mice. They were effectively deliv-
ered and accumulated in the inflamed joints due to RGD peptides. After delivery, 
heat was generated upon NIR exposure due to Au, and the MTX was then rapidly 
released from PLGA nanoparticles. The application of this multifactorial NP in 
CIA mice had better therapeutic efficacy with a much smaller dose of MTX, when 
compared to conventional treatment [25]. These results demonstrate that the tar-
geted NPs treatment is a useful and effective strategy for increasing the therapeutic 
efficacy and decreasing side effects of drugs used in the treatment of RA.
Steroids have been used for the treatment of chronic inflammatory disorders 
for decades [26]. Normally, to reach efficacious concentrations in the blood, they 
are frequently injected in high doses due to their rapid clearance from the body. 
However, the chronic use of corticosteroids is associated with severe side effects 
such as osteoporosis, hypertension, and weight gain. Therefore, current corticoste-
roids should have active targeting, controlled release and retention in the inflamed 
tissue. This could be done using engineered nanomaterials as delivery vehicles. In 
one study, glucocorticoids were loaded into liposomes to prolong the drug circula-
tion time and change drug distribution. As a consequence, number of injections 
and doses were reduced while still achieving similar efficacy to that of free gluco-
corticoid in rat models of rheumatoid arthritis [26].
Nano-carriers that were also successful in delivering anti-inflammatory drugs 
were PAMAM dendrimers [17, 26]. In one study, they have been used to deliver 
Translational Studies on Inflammation
8
indomethacin to reduce inflammation in the rat model of arthritis. The polyethyl-
ene glycol (PEG) dendrimers were functionalized with folate as a targeting ligand 
to target only activated macrophages, since folate receptor is expressed on activated 
macrophages only and not on resting ones. This folate-PEG-PAMAM dendrimer 
was loaded with indomethacin to study its anti-inflammatory effect. This conjuga-
tion resulted in a 10–20-fold increase in drug loading efficiency and was found to 
release indomethacin in the joints in a sustained manner [17].
4.2 Dermatitis
Dermatologic therapy is mainly aimed to prevent or decrease inflammation in 
the skin. Topical corticosteroids are the keystone of dermatologic therapy and have 
been used for various inflammatory conditions for their treatment or prevention 
[11]. Corticosteroids are often prescribed, though their use can carry significant 
side effects, as mentioned earlier.
In several studies, SLN corticosteroid formulations showed increased penetra-
tion compared to its traditional counterparts, resulting in penetration beyond the 
epidermis and into the dermis [11]. Moreover, SLN provide the added benefit of 
sustained release, which is a desirable feature for controlling concentration of drug 
in tissue over time; these properties may improve side effect profiles and dosing 
schedules of drugs.
NSAIDs are another main drug used in the treatment of inflammatory diseases 
because of their excellent anti-inflammatory and analgesic actions [10]. However, 
NSAIDs are associated with serious adverse effects. Therefore, whenever possible, 
drugs are used topically for dealing with local inflammatory diseases. Topical oint-
ments that contain NSAIDs nanoparticles were studied for skin penetration, safety, 
and anti-inflammatory effects in animal models of acute and chronic inflammation. 
In one study, two ointments, one with normal NSAIDs and the other containing 
NSAIDs in nanoform, were compared [10]. Following the application of both, the 
study revealed that NSAID in the nanoform had increased penetration of the drug 
into the skin compared with the normal NSAID, suggesting a higher local activity 
of NSAID nanoform when applied to the skin. In chronic inflammation model, both 
formulations decreased foot swelling in a time-dependent manner. However, the 
healing rate at 7 days of post treatment was significantly higher following treat-
ment with NSAID nanoform compared with the normal NSAID [10]. Moreover, 
the concentration of NSAID nanoform was much lower than those required of the 
normal NSAID. Hence, the potency of the nanoformulations is much higher than 
normal treatment [10]. NSAID nanoformulations are expected to be the basis for 
new dermatological products, due to their effective treatment and low side effects.
Another major dermatological product that is used by many consumers is 
sunscreen. Sunscreens are important tools for skincare and the first line of choice 
for the prevention of inflammation caused by ultraviolet (UV) rays. UV filters 
are crucial for the prevention of sunburn and UV-induced mutations that may 
lead to skin cancer. Inorganic UV filters such as titanium oxide (TiO2) and zinc 
oxide (ZnO) have been used in sunscreen formulations for a long time, and they 
are effective in protecting against both UVA and UVB rays. Despite that, TiO2 and 
ZnO filters leave an opaque white residue on the skin, which limits its use by many 
customers [11]. However, by reducing TiO2 and ZnO sizes to the nanoscale, the 
production of translucent products is possible rather than the white coarse raw 
material. It has been shown that sunscreens using particles between 40 and 60 nm 
are capable of providing good transparency without weakening UVA and UVB 
protection [27]. Although there has been some concern about the use of nanoma-
terials in sunscreens, there is no indication that the use of TiO2 or ZnO holds any 
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danger, and studies showed that nanoparticle preparations do not penetrate past the 
stratum corneum [28]. Therefore, further study is still needed to fully evaluate the 
safety of these filters and fully prove their safety.
4.3 Asthma
Asthma is a chronic inflammatory condition characterized by narrowing and 
swelling of the airways with extra production of mucus, which makes it difficult for 
the person to breathe [29]. Theophylline is a drug that had been used conventionally 
worldwide for the treatment of allergic asthma for several years [30]. Although it’s 
still widely prescribed, its use has decreased due to the use of inhaled glucocorti-
coids instead. Moreover, theophylline has severe side effects due to its low therapeu-
tic window, such as nausea, headache, and cardiac arrhythmias, which limits its use. 
The adsorption of theophylline to chitosan nanoparticles, modified by the addition 
of thiol groups, was studied in vivo using mouse models of allergic asthma [29].
Chitosan is a polymer derived from chitin that has been used for nanodrug 
delivery due to its beneficial properties such as biocompatibility, biodegradability, 
and bio-adhesiveness [31]. The mice were treated intranasally with theophylline 
alone, chitosan nanoparticles alone, or theophylline adsorbed to chitosan nanopar-
ticles [29]. The effects of theophylline on cellular infiltration, histopathology 
of lung sections, and apoptosis of lung cells were investigated to determine the 
effectiveness of theophylline chitosan NPs as a drug-delivery vehicle for theophyl-
line. Intranasal delivery of theophylline conjugated nanoparticles augmented the 
anti-inflammatory effects of the drug compared to theophylline administered alone 
[29]. Thus, the clinical effects of theophylline in treating asthma could be enhanced 
through the use of nanodrug delivery system. Nasal drug delivery is indeed a 
promising technique because of the large surface area in the nose, high blood flow, 
avoidance of first-pass metabolism, and the quick onset of pharmacological activity. 
Furthermore, it is reasonable to point out that the bioavailability, adsorption, and 
residence time of drugs administered through the nasal route would be increased 
using drug delivery carriers such as nanoparticles [32].
4.4 Inflammatory bowel disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major types of 
inflammatory bowel disease (IBD). IBD is a chronic but relapsing inflammatory 
disorder of the gastrointestinal tract [33]. UC is characterized by inflammation 
that is limited to the colon, while CD involves any part of the gastrointestinal 
tract. Abdominal pain, diarrhea, and rectal bleeding are frequent symptoms 
in patients suffering from IBD [33]. For years, the conventional treatment 
of IBD consisted of anti-inflammatory medications, such as corticosteroids, 
aminosalicylates, and immune suppressants. However, these drugs have several 
side effects due to their unspecific targeting upon administration. A promising 
strategy toward IBD treatment would be to selectively target the inflamed colonic 
tissue in order to decrease side effects and increase therapeutic efficacy of the 
drug administered.
In one study they used mesalamine, an anti-inflammatory medication used 
conventionally to treat UC, in a nanoparticle formulation [34]. Free mesalamine 
undergoes rapid and almost complete systemic absorption from the intestine, 
which causes side effects and drug loss, lowering the therapeutic effect of the 
medication. The drug then undergoes extensive metabolism. Therefore, it is 
important to deliver mesalamine (5ASA) locally to the colon, in order to reduce 
the systemic drug absorption and thus slow down the metabolism. The drug 
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was covalently bound to a NP matrix polymer. Experiments in mice with colon 
inflammation showed a distinct retention of the mesalamine inside the NP 
matrix, which allowed efficient colonic targeting and slowed down the release of 
the drug. This approach elevated the selectivity of the drug toward the inflamma-
tion site by decreasing the rapid drug release in the proximal intestine after oral 
administration [34].
Nano-drug delivery represents a promising approach in inflammatory disorders, 
mostly due to their accumulation in the inflamed regions [33]. In another study, 
the drug release was triggered by the sensitivity of polymer to pH during gastroin-
testinal (GI) transit. Scientists combined PLGA nanoparticles with pH-triggered 
polymer, to provide both specific accumulation in inflamed tissue and selective 
drug release in the colon [33]. They used curcumin (C) as the drug of choice to 
treat IBD, which is known for decades for its anti-inflammatory, antioxidant, 
antimicrobial, anticarcinogenic, and hepato-protective effects. Anti-inflammatory 
effects of C have been studied in several diseases before, such as Alzheimer’s 
disease, Parkinson’s disease, multiple sclerosis, and cerebral injury [35]. However, 
we must note that raw C is known for its poor solubility and thus low bioavailability. 
Moreover, it has a high rate of metabolism and rapid elimination. Thus, an IBD-
specific delivery system is needed to protect C from fast degradation. This study 
aimed to evaluate the effects of C loaded in polymeric pH-sensitive nanoparticles 
in the treatment of IBD. They were also compared to a C suspension to assess the 
selectivity and specific delivery of C to the colon. The negative charge of the surface 
of nanoparticles attracted them to positively charged ulcerated tissues [36]. Hence, 
C-NPs exhibited suitable physicochemical characteristics, due to their small size 
and opposite surface charge, for colonic delivery. In vitro studies reported that 
encapsulated C was found to cross through the epithelial barrier better than C 
suspension [33].
4.5 Alzheimer’s disease
AD is a type of chronic low-level inflammation that mainly affects the elderly 
[37]. It’s considered as a progressive and devastating neurodegenerative disorder 
that is characterized by cognitive deterioration and decline in the quality of the 
patient’s life [38]. An enormous amount of in vivo and in vitro research was con-
ducted by many groups to study the effect of NPs on the treatment of AD. The 
following are some examples of nanomaterials that are intended to target the brain 
and treat AD:
Albumin NPs loaded with tacrine, which was an AD medication previously, 
was synthesized and administered through the intranasal route of sheep to avoid 
the first-pass metabolism of the drug and deliver it rapidly to the brain. Due to 
the small size and large surface area of albumin NPs, the delivery of tacrine was 
improved through the mucosa to the brain. This research was tested on sheep nasal 
mucosa in permeation cell [39].
Dendrimers, as mentioned earlier, are globular macromolecular structures with 
a densely packed surface. It was found that dendrimers could block the aggrega-
tion of Amyloid β (Aβ), which is one of the causes of AD. This is by binding to the 
protofibrils and fibrils, therefore preventing the cytotoxic effect of Aβ plaques. In 
one study it was suggested that conjugated and unconjugated dendrimers had the 
ability to separate Aβ deposits in vitro [40].
Gold (Au) NPs were designed to dissolve the Aβ aggregates by the use of local 
thermal energy at a molecular level and preventing further aggregation. When Au 
NPs attach to Aβ aggregates and a weak microwave field is applied, they produce 
thermal energy which dissolve the aggregation and prevent them from reforming. 
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Au NPs are known to have the advantage of large surface area, biocompatibility, and 
small size which make them very suitable in this application [41].
Polymeric NPs such as PLGA have great biocompatibility and biodegradabil-
ity properties. They have the ability to encapsulate different kind of drugs and 
transport them to the brain by surface modification. For example, curcumin has 
been encapsulated by PLGA in several studies. This formulation was found to be a 
potential candidate for the treatment of AD due to the great properties of curcumin 
as mentioned earlier. Curcumin was found to bind to the Aβ plaques and disaggre-
gating them, due to its anti-amyloid property, which makes this C-NP formulation a 
very promising drug in the treatment of AD [41].
5. Future directions
Anti-inflammatory effects of engineered nanomaterials can be intentionally 
achieved. This is by modulating the nanoparticle physicochemical properties and 
by using nanoparticles as carriers for anti-inflammatory agents. However, struc-
ture activity relationship (SAR) studies are needed to further improve this area 
of nanotechnology. Despite the huge amount of benefits that nanoparticle holds 
as drug carriers, there are still some disadvantages [13]. For example, NPs might 
generate toxicity due to their small size, which widen the biodistribution of the 
drug in the body. Hence, increasing the drugs’ potency, which although beneficial, 
also might affect the immune response of the body and trigger toxicity. Moreover, 
clinical researchers have mentioned some negative factors, such as high cost and the 
difficulty of scaling-up processes [1]. Therefore, future nanodrug delivery studies 
are recommended, and these studies should focus on toxicity and on identifying 
key elements like dose, route of administration, physicochemical properties, and 
composition that might provoke toxicity. Understanding what makes the same 
nanoparticle beneficial in one model and toxic in another model is critical. This will 
aid drug delivery formulation scientists in choosing appropriate nanoparticle carri-
ers and will clearly enhance the rapidly growing field of nanodrug delivery.
6. Conclusion
Most drugs available nowadays are limited by their poor solubility, number of 
side effects, frequent dosing, and nonspecific delivery. Therefore, scientists have 
shifted their research to using nanoparticles for the delivery of drugs to avoid 
those limitations. NPs are now studied to deliver two or more drugs simultaneously 
for combination therapy, aiming to decrease frequency of dosing and number 
of medications a patient is receiving and thus increasing compliance. The main 
advantage of using NPs is that they could be modulated and specifically targeted 
to match the need. Therefore, the production of nanomaterials as drug delivery 
carriers can offer new opportunities to provide more focused and precise treat-
ment of inflammatory diseases and improve the potential therapeutic effective-
ness of available medications [17]. We covered in this chapter the advantages of 
nanotechnology in the medical field and the different kinds of NPs available. We 
also mentioned different kinds of inflammatory diseases such as arthritis, asthma, 
and Alzheimer’s disease and how nanoparticles were able to positively contribute 
in their treatment. Despite the many technical, regulatory, and legal challenges, 
the development of these technologies on a large scale would face, there is no doubt 
that there is enough desire to overcome these challenges to improve the quality of 
life and benefit the society [2].
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AD Alzheimer’s disease
Aβ amyloid β
CD Crohn’s disease
CIA collagen-induced arthritis
C curcumin
DMARDs disease-modifying antirheumatic drugs
IBD inflammatory bowel disease
5ASA mesalamine
MTX methotrexate
NPs nanoparticles
NIR near-infrared radiation
NSAIDs nonsteroidal anti-inflammatory drugs
PLA poly-lactic-acid
PLGA poly-lactic-co-glycolic-acid
PEG polyethylene glycol
RA rheumatoid arthritis
SAR structure activity relationship
SLN solid lipid nanoparticles
TiO2 titanium oxide
UC ulcerative colitis
UV ultraviolet
ZnO  zinc oxide
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